Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (1): 11-15.doi: 10.6040/j.issn.1671-7554.0.2018.1053

Previous Articles    

Chinese prostate cancer screening: current situation and challenges

ZHU Gang, ZHANG Kai   

  1. Department of Urology, Beijing United Family Hospital and Clinics, Beijing 100015, China
  • Published:2022-09-27

PDF (PC)

204

Abstract: The incidence of prostate cancer in China has been increasing rapidly in recent years. Randomized studies in Europe have showed that PSA-based screening can reduce mortality, but it may lead to overdiagnosis and subsequent 山 东 大 学 学 报 (医 学 版)57卷1期 -朱刚,等.中国前列腺癌筛查的现状和挑战 \=-overtreatment. Large-scale randomized controlled prostate cancer screening has not yet been conducted in China. Emerging techniques and strategies may improve prostate cancer screening; however, they will surely meet challenges which require new solutions.

Key words: Prostate cancer, Screening, China, Overdiagnosis, Overtreatment

CLC Number: 

  • R697
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2] Wong MC, WB Goggins, HH Wang, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries[J]. Eur Urol, 2016, 70(5): 862-874.
[3] Center MM, A Jemal, J Lortet-Tieulent, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6): 1079-1092.
[4] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[5] US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement[J]. JAMA, 2018, 319(18): 1901-1913.
[6] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study[J]. N Engl J Med, 2009, 360(13): 1320-1328.
[7] Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012, 366(11): 981-990.
[8] Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer(ERSPC)at 13 years of follow-up[J].The Lancet, 2014, 384(9959): 2027-2035.
[9] Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia[J]. Asian J Urol, 2017, 4(2): 86-95.
[10] Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up[J]. J Natl Cancer Inst, 2012, 104(2): 125-132.
[11] Shoag JE, Mittal S, Hu JC. More on reevaluating PSA testing rates in the PLCO trial[J]. N Engl J Med, 2016, 375(15): 1500-1501.
[12] Gao HW, Li YL, Wu S, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen[J]. Asian J Androl, 2005, 7(2): 159-163.
[13] Chen R, Sjoberg DD, Huang Y, et al. Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with Western cohorts[J]. J Urol, 2017, 197(1): 90-96.
[14] Chen R, Ren SC, Chinese Prostate Cancer Consortium, et al. Prostate cancer in Asia: a collaborative report[J]. Asian J Urol, 2014, 1(1): 15-29.
[15] Weiner AB, Matulewicz RS, Eggener SE, et al. Increasing incidence of metastatic prostate cancer in the United States(2004-2013)[J]. Prostate Cancer Prostatic Dis, 2016, 19(4): 395-397.
[16] Bokhorst LP, Venderbos LD, Schröder FH, et al. Do treatment differences between arms affect the main outcome of ERSPC rotterdam?[J]. J Urol, 2015, 194(2): 336-342.
[17] Sartori DA, Chan DW. Biomarkers in prostate cancer: whats new?[J]. Curr Opin Oncol, 2014, 26(3): 259-264.
[18] Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy[J]. Eur Urol, 2014, 66(5): 906-912.
[19] Na R, Ye DW, Liu F, et al. Performance of serum prostate-specific antigen isoform[-2] proPSA(p2PSA)and the prostate health index(PHI)in a Chinese hospital-based biopsy population[J]. Prostate, 2014, 74(15): 1569-1575.
[20] Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999, 59(23): 5975-5979.
[21] Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3(PCA3): development and internal validation of a novel biopsy nomogram[J]. Eur Urol, 2009, 56(4): 659-667.
[22] Chunhua L, Zhao H, Zhao H, et al. Clinical significance of periphreal blood PCA3 gene expression in eraly diagnosis of prostate cancer[J]. Transl Oncol, 2018, 11(3): 628-632.
[23] Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer[J]. Eur Urol, 2010, 57(1): 79-85.
[24] Chen R, Xie LP, Xue W, et al. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy[J]. Urol Oncol, 2016, 34(9): 416.e1-7. doi:10.1016/j.urolonc.2016.04.004.
[25] Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2[J]. Eur Urol, 2016, 69(1): 16-40.
[26] Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012[J]. Eur Radiol, 2012, 22(4): 746-757.
[27] Turkbey B, Choyke PL. PIRADS 2.0: what is new?[J]. Diagn Interv Radiol, 2015, 21(5): 382-384.
[28] Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis[J]. Eur Urol, 2015, 68(3): 438-450.
[29] 熊轶, 张古田, 汪维, 等. MRI/US成像融合引导的经会阴前列腺穿刺活检的单中心研究[J]. 临床泌尿外科杂志, 2018, 33(1): 39-43. XIONG Yi, ZHANG Gutian, WANG Wei, et al. MRI/US imaging fusion guided transperineal prostate biopsy: a research in single center[J]. Journal of Clinical Urology, 2018, 33(1): 39-43.
[30] Bjurlin MA, Mendhiratta N, Wysock JS, et al. Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment[J]. Cent European J Urol, 2016, 69(1): 9-18.
[31] Wegelin O, van Melick HHE, Hooft L, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. is there a preferred technique?[J]. Eur Urol, 2017, 71(4): 517-531.
[32] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent[J]. Eur Urol, 2017, 71(4):618-629.
[33] Kasivisvanathan V, AS Rannikko, M Borghi, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis[J]. N Engl J Med, 2018, 378(19): 1767-1777.
[1] WANG Jing, XIE Yan, LI Peilong, DU Lutao, WANG Chuanxin. Value of abnormal methylation of cg16212145 on GZMB gene in early screening of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 26-34.
[2] SUN Haoyu, JIANG Xin, CHEN Shouzhen, QU Sifeng, SHI Benkang. Multiparametric magnetic resonance imaging combined with prostate health index in the diagnosis of prostate cancer in 142 patients within PSA grey zone [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 46-50.
[3] XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang. Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 51-56.
[4] Yonggang SU,Rui WANG,Tongwei YANG. Influencing factors and preventive measures of elderly suicide from the perspective of Healthy China Initiative [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 8-13.
[5] XU Xiaoming, KONG Yiting, LIU Chuan, MING Ying, KUANG Li. Research progress of suicide warning systems for adolescents and young adults [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 69-74.
[6] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[7] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[8] SUN Dingqi, FU Qiang, ZHANG Hui, LIU Shuai, DIAO Tongxiang, CAO Qingwei, ZHANG Keqin. Clinical value of targeted multiparameter MRI and transrectal ultrasonography fusion prostate biopsy for the detection of PI-RADS≥3 prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 108-113.
[9] YANG Jiulong, YU Tao, XUE Fuzhong. Distribution of cerebrovascular stenosis and construction of a screening model [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 114-119.
[10] LÜ Jiaju, HU Jialin, DING Sentai. Advances in focal therapy for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 1-5.
[11] ZHOU Fangjian, HUANG Hua, LI Yonghong. Focal cryoablation for prostate cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(1): 6-10.
[12] YANG Haixia, CHENG Kai, HOU Qian, ZHANG Min, SUN Ming, ZHANG Linna. Retrospective analysis of eye disease screening for 0-6 years old infants in Jinan City during 2015 and 2017 [J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 41-46.
[13] LIU Qiyong. Protecting human health by mitigation and adaptation to climate change [J]. Journal of Shandong University (Health Sciences), 2018, 56(8): 3-6.
[14] ZHANG Dandan, XIE Hongqiang, WU Qianqian, LI Hongchang, ZHU Yueting, LU Juanjuan, JIANG Wenjie, YAN Junhao. Clinical treatment value of preimplantation genetic screening for unexplained repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2018, 56(4): 64-69.
[15] MAO Shaowei, LU Guoliang, LI Liang, XIA Qinghua. Valproic acid augments the anti-tumor potential of metformin in PC-3 cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 48-53.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd